Although there was weak evidence of possible association between the presence of B-CLS > 1 and clinical outcomes in the HER2 + ER− cohort (p = 0.099) (Supplementary Fig. 1c), there was evidence of association between the presence of B-CLS > 1 and reduced time to metastatic disease in the HER2 + ER + cohort (p = 0.019) (Supplementary Fig. 1d). The gene discussed is ERBB2; the disease is metastatic neoplasm.